The EUFOREA pocket guide for chronic rhinosinusitis.

P W Hellings,W J Fokkens, R Orlandi, G F Adriaensen, I Alobid,F M Baroody, L Bjermer,B A Senior,A Cervin,N A Cohen,J Constantinidis,E De Corso,M Desrosiers, Z Diamant,R G Douglas, S Gane, P Gevaert, J K Han,R J Harvey,C Hopkins, R C Kern, B N Landis, J T Lee, S E Lee,A Leunig,V J Lund,M Bernal-Sprekelsen, J Mullol, C Philpott,E Prokopakis, S Reitsma,D Ryan, S Salmi,G Scadding, R J Schlosser, A Steinsvik, P V Tomazic,E Van Staeyen,T Van Zele,O Vanderveken, A-S Viskens,D Conti,M Wagenmann

Rhinology（2023）

引用 4|浏览38

暂无评分

摘要

Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要